P 113D

Drug Profile

P 113D

Alternative Names: P-113 pulmonary spray - Demegen; P113D

Latest Information Update: 25 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Demegen
  • Class Amino acids; Antibacterials; Antifungals; Peptide antibiotics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 27 Jun 2003 Suspended - Preclinical for Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
  • 05 Nov 2002 P 113D has received orphan drug status for Cystic fibrosis in USA
  • 03 Apr 2002 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top